Authors

Brian M. Slomovitz, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System

Latest:

Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)

Dr. Brian Wolpin discusses updated safety and efficacy results from the Phase 1 study of RMC-6236, a RAS(ON) multi-selective inhibitor, highlighting its promising activity, manageable safety profile, and encouraging survival outcomes in patients with RAS mutant pancreatic ductal adenocarcinoma.

Brian Nussenbaum, MD

Latest:

Dr. Nussenbaum on Organ Preservation for Patients With Larynx Cancer

Brian Nussenbaum, MD, Christy J. and Richard S. Hawes III Professor, Otolaryngology-Head and Neck Surgery, director, Head and Neck Surgical Oncology, vice chair of Clinical Affairs, patient safety officer, Washington University School of Medicine in St. Louis, discusses which patients with larynx cancer are eligible for organ preservation surgery.

Brian Olsen, MD

Latest:

Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case Report

This is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Brian Orr, MD

Latest:

Dr. Orr on Ongoing Biomarker Research in Ovarian Cancer

Brian Orr, MD, an assistant professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at University of Pittsburgh Medical Center, discusses ongoing biomarker research for immunotherapy in ovarian cancer.

Brian Rini, MD

Latest:

Dr Rini on the FDA Approval of Belzutifan in Relapsed/Refractory RCC

Brian I. Rini, MD, FASCO, shares the importance of the FDA approval of belzutifan in patients with advanced renal cell carcinoma.

Brian Rini,MD, Cleveland Clinic Lerner College of Medicine

Brian Rini,MD, Cleveland Clinic Main Campus

Brian T. Burgess, DO

Latest:

Dr. Burgess on PARP Resistance in Ovarian Cancer

Brian T. Burgess, DO, first-year fellow, University of Kentucky Markey Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

Brian T. Hill, MD, PhD

Latest:

Expert Insights into Investigation Therapies for CLL

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

Brian Van Tine, MD, PhD, Washington University

Briana Patterson, MD

Latest:

Dr. Patterson on Off-Target Effects With TKIs in Pediatric CML

Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses the off-target effects with tyrosine kinase inhibitors (TKIs) in pediatric patients with chronic myeloid leukemia (CML).

Brice Labruzzo Mohundro, PharmD

Latest:

On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies

A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.

Bridget F. Koontz, MD

Latest:

Dr. Koontz on Next Steps for Study of LHRH in Prostate Cancer

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Bridgett Harr, CNP

Latest:

Bridgett Harr on Managing Long-term Side Effects in Head and Neck Cancer

Bridgett Harr, CNP, radiation oncology, Cleveland Clinic, discusses survivorship and managing long-term side effects in head and neck cancer.

Brielle Benyon

Latest:

Rewriting the Rules for a Better Future of Cancer Care

Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in diversifying clinical trials and improving quality of life.

Brielle Urciuoli

Latest:

Persistence and the Quest for Innovation Guided a Radiotherapy Pioneer

Herman D. Suit, MD, MSc, PhD, a leader in the field of radiation oncology whose innovations lessened the need for radical surgery and improved outcomes for patients, was honored in the Radiation Oncology category with a 2017 Giants of Cancer Care® award.

Brielle Uricioli

Brigid Killelea, MD, MPH, FACS

Latest:

Dr. Brigid Killelea on Nipple-Sparing Mastectomy for Breast Cancer

Brigid Killelea, MD, MPH, FACS, associate professor of surgery (oncology), Yale Cancer Center, discusses the potential of nipple-sparing mastectomy for women who undergo surgery for breast cancer.

Brigitta Torster

Latest:

NO-Naproxen May Protect Against Colorectal Cancer

A study presented at the AACR 101st Annual Meeting 2010 by researchers from the Fox Chase Cancer Center, Philadelphia, Pennsylvania, provides further evidence that non-steroidal anti-inflammatory drugs (NSAIDs) are promising chemopreventive agents with activity against colorectal cancer.